GlassScriptPhysician profile
Benjamin David Bernstein
NPI 1831155704
$6,296.77
in general payments reported to CMS, 2019-2025
31 companies · $854 in 2025
The $854 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $608 · 2020: $539 · 2021: $656 · 2022: $1,074 · 2023: $1,084 · 2024: $1,482 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,220 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,220.48 |
| Education | $199.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $966.81 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $945.75 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $608.38 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $477.73 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $333.91 | 2019-2025 | Siliq, Targretin, Arazlo |
| Hill Dermaceuticals, INC. | $309.52 | 2024 | Tolak |
| Lilly USA, LLC | $307.15 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $223.46 | 2019-2025 | Dupixent |
| Dermavant Sciences, INC. | $219.39 | 2022-2024 | Vtama |
| Amgen INC. | $211.75 | 2020-2025 | Otezla, Otezla |
| Ucb, INC. | $210.55 | 2019-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $206.41 | 2020-2025 | |
| Almirall LLC | $181.46 | 2019-2025 | Klisyri, Seysara |
| Galderma Laboratories, L.P. | $156.53 | 2022-2025 | Nemluvio, Aklief, Oracea |
| Biofrontera INC. | $134.56 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $118.76 | 2022-2024 | Sotyktu |
| Pfizer INC. | $96.93 | 2021-2022 | |
| Leo Pharma INC. | $95.56 | 2022-2025 | Anzupgo |
| Mayne Pharma Commercial LLC | $94.96 | 2019-2020 | |
| Incyte Corporation | $81.55 | 2021-2024 | Opzelura |
| Verrica Pharmaceuticals INC. | $54.79 | 2023-2024 | Ycanth |
| Celgene Corporation | $43.02 | 2019 | |
| Prugen, INC. Pharmaceuticals | $35.55 | 2019 | |
| Arcutis Biotherapeutics, INC. | $34.42 | 2023-2024 | Zoryve |
| Nabriva Therapeutics, Plc | $32.75 | 2021-2022 | |
| Organon LLC | $31.23 | 2025 | |
| Vyne Pharmaceuticals INC. | $24.60 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.60 | 2023 | Cyltezo |
| Dermira, INC. | $14.24 | 2020 | |
| Genentech USA, INC. | $13.88 | 2019 | |
| Epi Health, LLC | $13.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Bernstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.